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ABSTRACT In 5% (v/v) triﬂuoroethanol, pH 5.5, 25C one of the acylphosphatases from Drosophila melanogaster (AcPDro2)
forms ﬁbrillar aggregates that bind thioﬂavin T and Congo red and have an extensive b-sheet structure, as revealed by circular
dichroism. Atomic force microscopy indicates that the ﬁbrils and their constituent protoﬁlaments have diameters compatible with
those of natural amyloid ﬁbrils. Spectroscopic and biochemical investigation, carried out using near- and far-UV circular
dichroism, intrinsic and 1-anilino-8-naphthalenesulfonic acid-derived ﬂuorescence, dynamic light scattering, and enzymatic
activity assays, shows that AcPDro2 has, before aggregation, a secondary structure content packing around aromatic and
hydrophobic residues, hydrodynamic diameter, and catalytic activity indistinguishable from those of the native protein. The
native protein was found to have the same conformational stability under native and aggregating conditions, as determined from
urea-induced unfolding. The kinetic analysis supports models in which AcPDro2 aggregates initially without need to unfold and
subsequently undergoes a conformational change into amyloid-like structures. Although fully or partially unfolded states have a
higher propensity to aggregate, the residual aggregation potential that proteins maintain upon complete folding can be physio-
logically relevant and be directly involved in the pathogenesis of some protein deposition diseases.
INTRODUCTION
A number of pathological conditions are associated with the
conversion of a speciﬁc protein or peptide from its soluble
state into well organized ﬁbrillar aggregates generally re-
ferred to as amyloid or amyloid-like ﬁbrils (1–4). These ﬁbrils
generally consist of 2–6 protoﬁlaments, each ;2–5 nm in
diameter, that generally twist together to form ﬁbrils that are
typically 7–13 nmwide (5,6). In each individual protoﬁlament
the protein molecules are arranged to form b-strands that run
perpendicular to the long axis of the ﬁbril or protoﬁlament
(5,7). The ﬁbrils have the ability to bind speciﬁc dyes such as
thioﬂavin T (ThT) and Congo red (CR) (8–10), although the
speciﬁcity of binding of CR to amyloid and the resulting
yellow-green birefringence has recently been questioned
(11,12).
In some of the pathological conditions associated with
formation of amyloid-like structures the precursor protein is
normally folded, in its soluble state, into a globular unit with
persistent secondary structure and long-range interactions.
Examples include b2-microglobulin, transthyretin, lysozyme,
immunoglobulin light chain, superoxide dismutase, ataxin-3,
cystatin c, and gelsolin (3,13,14). Such proteins spend most
of their lifetime in a folded state, but can transiently adopt a
partially or totally unfolded state, for example during biosyn-
thesis, translocation or stress conditions. Partially or totally
unfolded states can also be in equilibrium with the native state
even under nonstress conditions; this may provide a pool of
protein molecules that can initiate and propagate the aggre-
gation process, especially when the native structure is de-
stabilized by mutations that shift the equilibrium toward the
unfolded state (14,15).
A major question that needs to be answered is whether
amyloid formation is initiated by such partially or totally un-
folded states that are only occasionally populated, or whether it
directly involves the native state. The observations that un-
folded states have a greater propensity than folded states to
aggregate, and that amyloid formation is often associated with
genetic mutations that can effectively destabilize the native
state, have led to the proposal that a conformational change is
the ﬁrst essential step in amyloidogenesis, at least for those
diseases associated with such globular proteins (3,16,17). How-
ever, recent observations have questioned the generality of this
mechanism. The pathogenic variant of ataxin-3, the protein
associated with spinocerebellar ataxia type-3, does not appear
to have a destabilized native structure, which leads to the
proposal that the pathway for ﬁbril formation is distinct from
that of unfolding (18). Amyloid formation by insulin is pre-
ceded by an oligomerization of the protein in which a native-
like content of a-helical structure is retained almost completely
(19). Within a group of variants of the protein S6 from Thermus
thermophilus, no signiﬁcant correlation was found between the
rate of ﬁbril formation, under conditions in which a quasinative
state was populated before aggregation, and the unfolding rate
or conformational stability (20). Aggregation of the acylphos-
phatase from Sulfolobus solfataricus into amyloid protoﬁbrils is
more rapid than unfolding under conditions in which the native
state is thermodynamically more stable than the major partially
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unfolded state (21). All of these observations suggest that an
association of protein molecules in their native-like states can
be the ﬁrst event in the aggregation of some globular proteins,
with the structural conversion into an amyloid conformation
occurring subsequently.
The study of amyloid formation under solution media in
which the protein is initially in a native-like conformation
is therefore of vital importance to understand aggregation
pathways that may occur in vivo. Our ability to distinguish
between mechanisms in which partial or full unfolding is
a ﬁrst step and others in which oligomerization precedes a
structural reorganization is important not just to clarify the
pathogenesis of speciﬁc protein deposition diseases, but also
to recognize the dangerous pathways from which proteins
generally need to escape to remain soluble in vivo. In this
work, we investigate the aggregation mechanism of a novel
acylphosphatase from Drosophila melanogaster (AcPDro2),
a 102-residue protein domain having a ferredoxin-like topol-
ogy in its native state (22,23). We will show that AcPDro2 self-
assembles under conditions in which the native structure is
highly populated and has a conformation no less stable than that
measured under native conditions in which aggregation is not
observed. The kinetic data rule out models in which a partial
unfolding of the protein is required to start aggregation.
MATERIALS AND METHODS
Materials
Thioﬂavin T (ThT), triﬂuoroethanol (TFE), dithiothreitol (DTT), urea,
Congo red (CR) and 8-anilino-1-naphthalenesulfonic acid (ANS) were
purchased from Sigma-Aldrich (St. Louis, MO). Triﬂuoroacetic acid was
purchased from Biosolve (Valkenswaard, The Netherlands). Formic acid
was purchased from Merck (Darmstadt, Germany). Benzoylphosphate was
synthesized and puriﬁed as described (24). AcPDro2 was expressed and
puriﬁed as described previously (22) and stored at 4C in 5 or 50 mM ace-
tate buffer, 2 mM DTT, pH 5.5. Protein concentration was determined
spectrophotometrically using an e280 value of 1.09 ml mg
1 cm1. Before
starting each experiment, the protein solution was centrifuged at 18,000 rpm
for 3–5 min and ﬁltered using 0.02 mm Anotop 10 ﬁlters (Whatman Inter-
national, Maidstone, UK).
ThT assay
AcPDro2 was incubated at a concentration of 0.4 mg ml1 in 50 mM acetate
buffer, 2 mMDTT, pH 5.5, at 25C in the presence of concentrations of TFE
ranging from 0 to 20% (v/v). At regular times 60 ml aliquots of each sample
were added to 440 ml of a solution containing 25 mM ThT, 25 mM
phosphate buffer, pH 6.0. The steady-state ﬂuorescence values of the
resulting samples were measured at 25C using a 2 3 10-mm-pathlength
quartz cuvette and a Perkin-Elmer (Wellesley, MA) LS 55 spectroﬂuorim-
eter equipped with a thermostated cell holder attached to a Haake (Karlsruhe,
Germany) F8 water bath. The excitation and emission wavelengths were 440
and 485 nm, respectively (9). ThT ﬂuorescence was plotted versus time and
ﬁtted to single exponential functions of the form
FðtÞ ¼ Feq1A expðkapptÞ; (1)
where F(t) is the ThT ﬂuorescence at time t, Feq is the maximum ThT ﬂuo-
rescence obtained at the end of the observed exponential phase, A is the
amplitude of the ﬂuorescence change, and kapp is the apparent rate constant.
Another set of data was collected after incubating the protein in 50 mM
formiate buffer, 5% (v/v) TFE, 25 mM NaCl, 2 mM DTT, pH 3.5, at 25C.
CR assay
AcPDro2 was incubated at a concentration of 0.4 mg ml1 for ;60 h in 50
mM acetate buffer, 2 mM DTT, pH 5.5, at 25C, in the presence of 0 or 5%
(v/v) TFE. In both cases, a 60 ml aliquot was mixed with a 440-ml solution
containing 20 mM CR, 5 mM phosphate buffer, 150 mM NaCl, pH 7.4, in
a reduced volume, 5-mm-pathlength quartz cuvette. Corresponding solu-
tions of CR without protein and protein with no CR were used as controls.
Optical absorption spectra were acquired from 400 to 700 nm by anUltrospec
2000 spectrophotometer (Pharmacia Biotech, Cambridge, UK). The spec-
trum obtained with buffer only was subtracted from all acquired spectra.
Tapping mode atomic force microscopy
AcPDro2 was incubated at a concentration of 0.4 mg ml1 in 50 mM acetate
buffer, 5% (v/v) TFE, 2 mM DTT, pH 5.5, 25C. Aliquots of 20 ml were
withdrawn at various times, deposited on freshly cleaved mica substrates and
dried under mild vacuum for 30 min. Tapping mode atomic force microscopy
(TM-AFM) images were acquired in air using a Dimension 3000 microscope
(Digital Instruments, Veeco, Santa Barbara, CA) equipped with a ‘‘G’’ scan-
ning head (maximumscan size 100mm). Single-beamuncoated silicon cantile-
vers were used (type RTESP, Veeco, Santa Barbara, CA). The drive frequency
was ;300 kHz; the scan rate was between 0.3 and 0.7 Hz.
Dynamic light scattering
Samples were prepared at ﬁnal AcPDro2 concentrations ranging from 0.3 to
1.0 mg ml1 in 50 mM acetate buffer, 2 mM DTT, pH 5.5, at 25C, in the
presence of 0% and 5% TFE. Each protein sample was prepared by diluting
a stocked protein sample and was immediately centrifuged (18, 000 rpm for
5 min) and ﬁltered (0.02 mm) shortly before acquiring its size distribution to
remove any preexisting aggregates and dust particles. A low-volume (45 ml)
black quartz cuvette with 10 mm light path was used. Data were obtained
with a Zetasizer Nano S dynamic light scattering (DLS) instrument (Malvern
Instruments, Worcestershire, UK) setting the appropriate viscosity and
refractive index parameters for each solution and keeping the temperature
at 25C during the measurements by means of a Peltier thermostating
system.
Far-ultraviolet circular dichroism
Samples of AcPDro2 were prepared at ﬁnal concentrations ranging from
0.01 to 0.8 mg ml1 in 5 mM acetate buffer, 2 mM DTT, pH 5.5, at 25C, in
the presence of 0–5% and 80% TFE, or 5 M urea with no TFE.
Far- ultraviolet (UV) circular dichroism (CD) spectra were acquired at 25C
immediately after diluting the stocked protein sample into these solutions.
Quartz cuvettes with pathlengths ranging from 1 to 10 mm were used,
depending on protein concentrations. A Jasco (Tokyo, Japan) J-810 spectro-
polarimeter equipped with a thermostated cell holder attached to a Thermo
Haake C25P water bath was used. Each spectrum of the protein was
recorded from 190 to 260 nm as the average of four scans, blank-subtracted,
processed using the adaptive smoothing method (25) and normalized to
mean residue ellipticity.
Near-UV CD
Samples of AcPDro2 were prepared at ﬁnal protein concentrations of 0.2
mgml1 in 5 mM acetate buffer, 2 mMDTT, pH 5.5, at 25C, in the presence
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of 0% and 5% (v/v) TFE, or 4.5 M urea. Near-UV CD spectra were acquired
at 25C from 250 to 350 nm, immediately after diluting the stocked protein
sample into these solutions. A 10-mm-pathlength quartz cuvette and the CD
instrument described in the Far-UV CD section were used. Due to the low
signal/noise ratio, spectra for the protein samples in 0% TFE and in 4.5 M
urea were recorded as the average of 40 separate scans, whereas 10 scans
were averaged for the protein sample in 5% TFE. Each spectrum was blank-
subtracted, processed using the adaptive smoothing method (25), and
normalized to mean residue ellipticity.
Intrinsic ﬂuorescence
AcPDro2 was diluted to a ﬁnal concentration of 0.02 mg ml1 in 5 mM
acetate, 2 mM DTT, pH 5.5, at 25C and in the presence of various de-
naturants. Fluorescence spectra were acquired immediately after dilution
using the cuvette and instrumental apparatus described in the ThT assay
section. Excitation wavelength was set at 280 nm and emission range was
from 300 to 450 nm. Each spectrum was recorded as the average of two
scans and smoothed using a moving average function with the statistical
mean of seven points.
ANS ﬂuorescence
AcPDro2 was diluted to a ﬁnal concentration of 0.02 mg ml1 in 55 mM
ANS, 50 mM acetate, 2 mM DTT, pH 5.5, at 25C. We prepared two
samples containing 0 and 5% TFE, respectively. Fluorescence spectra were
acquired immediately after dilution using the same cell and equipment de-
scribed in the ThT assay section. Excitation wavelength was set at 380 nm
and emission range was from 410 to 630 nm. Spectra were also acquired for
the corresponding solutions in the absence of protein. Each spectrum was the
average of two scans and was smoothed using a moving average function
with the statistical mean of seven points. ANS concentration was determined
spectrophotometrically using an e375 value of 8000 ml mmol
1 cm1.
Enzymatic activity
Enzymatic activity of AcPDro2 was tested in the presence of TFE
concentrations ranging from 0 to 5%, using a ﬁnal protein concentration
of 0.5 mg ml1 and 4 mM benzoylphosphate as a substrate, as described by
Ramponi et al. (26). Other experimental conditions were 50 mM acetate
buffer, 2 mM DTT, pH 5.5, at 25C. Activity was measured with a Perkin-
Elmer l 4 B UV-Vis spectrophotometer. The noncatalyzed spontaneous
hydrolysis of benzoylphosphate was subtracted from all measurements.
Measurements were performed immediately after addition of TFE, without
any incubation time.
Equilibrium unfolding
Unfolding of AcPDro2 was studied at equilibrium in the presence of dif-
ferent concentrations of TFE, ranging from 0 to 5% (v/v). For each
TFE concentration 30 samples were prepared containing 0.02 mgml1 protein
in 50 mM acetate buffer, 2 mM DTT, pH 5.5, and various urea concentra-
tions ranging from 0.1 to 8 M. The samples were left to equilibrate for a few
minutes at 25C. Fluorescence spectra were acquired at 25C using the cuvette
and instrumental apparatus described in the ThT assay section, with a
wavelength range between 300 and 450 nm and an excitation wavelength at
280 nm. Each spectrum was recorded as the average of two scans and
smoothed using a moving average function with the statistical mean of seven
points. The ﬂuorescence at 348 nm was plotted versus urea concentration and
the resulting plot was ﬁtted to the equation described by Santoro and Bolen
(27) to determine the free energy difference between the unfolded and folded
states of the protein in the absence of urea (DGUFH2O), the dependence of
DGUF on urea concentration (m value) and the midpoint of unfolding (Cm).
Stopped-ﬂow kinetics
Folding and unfolding of AcPDro2 were studied with a Bio-logic (Claix,
France) SFM-3 stopped-ﬂow device coupled to a ﬂuorescence detection sys-
tem and thermostated at 25C with a Neslab (Newington, NH) RTE-200
water-circulating bath. The excitation wavelength was 280 nm, and the
ﬂuorescence emitted above 320 nm was monitored using a bandpass ﬁlter.
All the experiments were performed in 50 mM acetate, 2 mM DTT, pH 5.5,
at a ﬁnal protein concentration of 0.02 mg ml1. In a ﬁrst set of unfolding
and folding experiments the protein was initially in 0 and 6 M urea,
respectively. Both reactions were initiated by 10-fold dilutions. Unfolding
and folding kinetics were studied at ﬁnal urea concentrations of 5.4 and 0.6
M, respectively, in the presence of TFE concentrations ranging from 0 to
8.25% (v/v). The dead time was 10.44 ms. The unfolding and refolding
traces were ﬁtted to single and double exponential functions, respectively, of
the form
yðtÞ ¼ q1 S
n
i¼1
Ai expðkitÞ; (2)
where y(t) is the ﬂuorescence at time t, q is the ﬂuorescence value at
equilibrium, Ai and ki are the amplitude and rate constant of the ith phase,
respectively, and n is the number of observed phases. In a second set of exper-
iments, the unfolding and folding kinetics were monitored at ﬁnal urea con-
centrations ranging from 1.80 M to 7.20 M for unfolding and from 0.50 M
to 3.20 M for folding. Finally, in a third set of experiments the protein
was unfolded in 2 M urea, 10 mM triﬂuoroacetic acid, pH 2.0. Folding was
initiated by a 20-fold dilution in 50 mm acetate buffer, pH 5.5, 2 mM DTT,
25C, at ﬁnal urea concentrations ranging from 0.1 to 1.8 M. These
experiments were performed both in 0% and 5% (v/v) TFE. In the second
and third sets of experiments the analysis was carried out at ﬁnal TFE
concentrations of 0 and 5% (v/v). The unfolding and refolding traces were
ﬁtted to Eq. 2 and the natural logarithm of ki was plotted versus urea con-
centration for both the analyses carried out in 0 and 5% TFE. The result-
ing plots were ﬁtted using the following equation, edited by Jackson and
Fersht (28):
ln k ¼ ln ½kH2OF expðmF ½UreaÞ1 kH2OU expðmU ½UreaÞ;
(3)
where kH2OF and k
H2O
U are the rate constants for folding and unfolding in the
absence of urea, respectively and mF and mU are the dependencies of ln kF
and ln kU on urea concentration, respectively.
RESULTS
Formation of amyloid-like structures at low
concentrations of TFE
AcPDro2 was incubated at a concentration of 0.4 mg ml1 in
50 mM acetate buffer, 2 mM DTT, pH 5.5, at 25C, at TFE
concentrations ranging from 0 to 20% (v/v). After 2 and 24 h,
the protein samples were subjected to the ThT assay (9). All
protein samples incubated at TFE concentrations .4–5%
(v/v) were able to increase signiﬁcantly the ﬂuorescence of
ThT, whereas no signiﬁcant aggregation was found to occur
at lower TFE concentrations after 24 h (Fig. 1 a). Aggre-
gation appears to be slightly lower in 20% than in 50%
(v/v) TFE, with no signiﬁcant differences in ThT binding
after 2 h and 24 h (data not shown).
The protein samples incubated for 60 h in 0 and 5% (v/v)
TFE were also subjected to the CR assay (8). The spectra
acquired for CR in the presence and absence of protein
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preincubated in buffer without TFE are superimposable (Fig.
1 b). The difference spectrum, obtained by subtracting the
spectra of protein only and CR only from the spectrum of CR
with protein, does not show a peak at 540 nm, indicating that
the protein is not able to bind to the dye and cause the char-
acteristic red shift from 490 to 540 nm (Fig. 1 b, inset). By
contrast, the spectrum acquired for CR in the presence of
protein preincubated in 5% (v/v) TFE exhibited a signiﬁcant
red shift relative to the spectrum of CR alone (Fig. 1 c). The
higher absorbance values found in the former at all wave-
lengths arises from the ability of the protein aggregates to
scatter the incident light, as shown by the spectrum acquired
for the protein only in the absence of CR (Fig. 1 c). The
difference spectrum, obtained as described above for the
analysis in the absence of TFE, shows a peak at 540 nm, as
expected for CR bound to ordered aggregates (Fig. 1 c,
inset).
Secondary structure of the aggregates was monitored using
far-UV CD (Fig. 1 d). Spectra were acquired using two sets of
protein samples, each at 0.1, 0.2, and 0.4 mg ml1 in 5% (v/v)
TFE. Although the ﬁrst set was preincubated for 48 h, the
other was tested immediately after the addition of TFE. The
CD spectra of the aggregated protein are signiﬁcantly differ-
ent from those obtained immediately after the addition of
TFE when the aggregates are not yet present (Fig. 1 d). This
indicates that a conformational change is associated with
AcPDro2 aggregation. The CD spectra of the aggregated
protein display a single minimum at;220–224 nm, typical of
aggregates having b-sheet structure (29). The peak is gen-
erally at 215–218 nm, but undergoes a red shift due to light-
scattering phenomena arising from the aggregates.
Protein samples incubated in 5% TFE were analyzed us-
ing TM-AFM. Since the sample was dried to facilitate its
adhesion to the mica substrate, the measured aggregate sizes
reported below are reduced with respect to fully hydrated
conditions, the shrinking factor being 2.0–2.5, as previously
evaluated (30). After 24 h of incubation, aggregates with a
twisted, ﬁbrillar appearance are observed (Fig. 2 a). The
ﬁbrils have a height of 2.86 0.2 nm, with the height reduced
at their ends to 1.8 6 0.1 nm. The typical ﬁbril length is 50–
200 nm. After 48 h of incubation, longer ﬁbrils (typically
from 300 nm to 1 mm) are found (Fig. 2 b). Twisted ﬁbrils
with a height of 3.66 0.1 nm result from the intertwining of
thinner ﬁlaments whose diameter exhibits a bimodal distri-
bution with peaks around 1.2 and 2.3 nm and mean value 1.9
6 0.1 nm. Given the shrinking factor of 2.0–2.5, the 3.6-nm-
high ﬁbrils and their constituent 1.9-nm-high ﬁlaments have
widths consistent with amyloid ﬁbrils and protoﬁlaments,
respectively. Overall, the aggregates formed from AcPDro2
analyzed here appear to have morphological, structural, and
tinctorial properties typical of amyloid-like structures.
AcPDro2 is initially in its native-like state
Next we investigated the conformational state adopted by
AcPDro2 in 5% (v/v) TFE before the aggregates form. This
was technically feasible due to the relatively slow kinetics
of the process that allowed a biophysical investigation to be
carried out before the aggregates accumulate signiﬁcantly.
DLS measurements were performed on protein samples with
and without 5% (v/v) TFE added immediately before the
measurements. Fig. 3 a shows two representative size
FIGURE 1 (a) AcPDro2 aggregation mea-
sured by ThT ﬂuorescence, after 2 h (s) and
24 h (d) of incubation in 0–20% (v/v) TFE.
(b and c) CR assay on AcPDro2 aggregates.
The protein was preincubated for;60 h in two
separate samples containing 0% TFE (b) and
5% TFE (c). Spectra were acquired for protein
in phosphate buffer (:, ‘‘spectrum 1’’), CR
(d, ‘‘spectrum 2’’), and protein in CR-
phosphate buffer (n, ‘‘spectrum 3’’). The insets
show the respective difference spectra, cal-
culated by subtracting spectra 1 and 2 from
spectrum 3. (d) Far-UV CD spectra of AcP-
Dro2 in 5% TFE at protein concentrations of
0.4 (:), 0.2 (d), and 0.1 mg ml1 (n). Spectra
were acquired immediately after (solid lines)
and 48 h after (dashed lines) incubation under
these conditions.
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distributions by light-scattering intensity obtained at a protein
concentration of 0.5 mg ml1, in 0% (solid line) and 5%
(dashed line) TFE. The peaks at 3.77 6 0.13 and 4.10 6
0.13 nm observed in 0 and 5% (v/v) TFE, respectively, are
consistent with the hydrodynamic diameter of native and
monomeric AcPDro2, as determined by the x-ray crystal-
lographic structure (23) (errors reported in the manuscript
indicate standard deviations). All pairs of measurements,
carried out at different protein concentrations, show that
the apparent hydrodynamic diameters measured in 5% (v/v)
TFE are within error of those measured in the absence of
TFE (Fig. 3 a, inset). This result led us to the conclusion that
a monomeric form of AcPDro2, with a compactness similar
to that of the native protein, is the most represented in solu-
tion before the aggregation process starts.
The secondary structure content of AcPDro2 before
aggregation was investigated using far-UV CD. The CD
spectra of AcPDro2, recorded immediately after the addi-
tion of 1, 2, 3, 4, and 5% (v/v) TFE, are very similar to that
obtained for the native protein in the absence of TFE. Fig.
3 b shows that the spectra in 0 and 5% (v/v) are highly
superimposable, both having a large negative band at 205–
235 nm, typical of an a/b protein. This result shows that the
protein does not undergo any detectable change in secondary
structure after the addition of small quantities of TFE, even at
a concentration able to induce aggregation. By contrast, the
CD spectra acquired in 80% (v/v) TFE and in 5 M urea with
no TFE indicate major changes in secondary structure com-
position under these conditions (Fig. 3 b).
The near-UV CD spectra are also highly superimposable
when recorded for protein samples in 0 and 5% TFE (Fig.
3 c). The broad peak at 262–280 nm and the two sharp peaks
at 286 and 295 nm are present in both spectra, indicating that
no modiﬁcations in protein structure packing, particularly
in anisotropy of aromatic residues, seem to occur after the
addition of 5% TFE. By contrast, the near-UV CD spectrum
of the protein sample denatured in 4.5 M urea, recorded as
a control, shows that AcPDro2 has lost its native packing
after denaturation (Fig. 3 c).
Modiﬁcations in the chemical environment around trypto-
phan residues were also monitored with ﬂuorescence spec-
troscopy (Fig. 3 d). AcPDro2 has two tryptophan residues at
positions 42 and 68, respectively. The intrinsic ﬂuorescence
spectra of the protein in 0–5% (v/v) TFE are very similar to
each other, as shown for the two representative spectra in 0 and
5% TFE (Fig. 3 d). We found no signiﬁcant differences for the
wavelength of maximum emission (lmax ¼ 350 nm) in 0–5%
TFE. The weak increase of ﬂuorescence emission from 0 to
5% TFE correlates linearly with TFE concentration (Fig. 3 d,
inset); hence, it is most likely attributable to solvent effects
rather than to a conformational change. On the other hand, the
spectra recorded in 80% (v/v) TFE and 5 M urea with no TFE
show a noticeable loss in total ﬂuorescence emission and a red
shift of the lmax value from 350 nm to 355 nm (80% TFE) and
358 nm (5 M urea).
Possible variations in the solvent exposure of hydrophobic
clusters after the addition of TFE have been further inves-
tigated using ANS. This dye is known to bind to clustered
hydrophobic residues that are exposed to the solvent in
a protein and hence to give rise to a blue shift and an increase
in ﬂuorescence emission intensity (31,32). Both the protein
samples in 0 and 5% (v/v) TFE were found to cause very
weak and very similar increases of ﬂuorescence emission of
ANS (Fig. 3 e). The difference spectra, obtained in each case
by subtracting the spectrum of free ANS from that recorded
in the presence of protein, exhibit lmax values of 480 and 490
nm for the protein in 0% and 5% (v/v) TFE, respectively,
a blue shift from the lmax of 515 nm for free ANS (Fig. 3 e).
This indicates that small fractions of ANS molecules are
bound to the protein, in both 0 and 5% TFE. The weak peaks
shown in the difference spectra may perhaps be attributed
to the ability of ANS to bind to cationic groups of the pro-
tein (33), since at pH 5.5 AcPDro2 has a net charge of
16. However, the fact that a similar relative increase of
ANS ﬂuorescence is caused by the protein in the two condi-
tions rules out that additional hydrophobic clusters become
superﬁcial after the addition of small amounts of TFE.
FIGURE 2 TM-AFM images (amplitude data; insets, height data) of
AcPDro2 aggregates obtained in 5% TFE after 24 h (a) and 48 h (b). Image
sizes are (a) 1.03 0.8 mm, inset 3803 320 nm; (b) 1.93 1.3 mm, inset 300
3 270 nm. The Z ranges for the height data reported in the insets are (a) 15
nm and (b) 10 nm. The aggregate sizes reported in the Results section were
obtained by measuring the aggregate height in cross section in the TM-AFM
images. The apparent size deduced visually from the image turns out to be
overestimated because of the broadening effects caused by the AFM tip in
the scan plane (30).
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The acylphosphatase activity of AcPDro2 was also deter-
mined in the presence of low concentrations of TFE, ranging
from 0 to 5% (v/v). The catalytic activity of acylphospha-
tases requires the correct spatial positioning of residues that
are relatively distant in the sequence, namely Arg-27, Asn-
45, and the residues of the loop 19GRVQGV24 (34). We
found that the ability of AcPDro2 to hydrolyze the acylphos-
phate bond did not change signiﬁcantly within the range of
TFE concentration tested (Fig. 3 f). Overall, the analysis
presented here indicates that the protein populated under
aggregating conditions, but before aggregation occurs, has
structural and catalytic properties indistinguishable from
those of the native protein under conditions in which it resists
aggregation.
Absence of destabilization under
aggregating conditions
Thermodynamic stability of native AcPDro2 has been
monitored by equilibrium denaturation experiments carried
out at TFE concentrations ranging from 0 to 5% (v/v). We
followed unfolding of AcPDro2 at equilibrium using urea
as a chemical denaturant and intrinsic ﬂuorescence as a spec-
troscopic probe. Fig. 4 a shows the unfolding curves normal-
ized to the fraction of folded protein with and without 5%
(v/v) TFE. The unfolding transitions appear to occur at simi-
lar urea concentrations and with similar cooperativities in the
two solution conditions (Fig. 4 a). The main thermodynamic
parameters of the unfolding reaction were inferred at all TFE
concentrations tested from the equilibrium curves assum-
ing a two-state model and using the equation described by
Santoro and Bolen (27). The free energy change upon
unfolding in the absence of urea (DGH2OUF) and the midpoint
of unfolding (Cm) were found to remain substantially un-
changed at the different TFE concentrations used (Fig. 4 b).
We concluded that addition of up to 5% TFE does not lead
to a substantial thermodynamic destabilization of the native
structure of AcPDro2.
Folding and unfolding kinetics of AcPDro2 were
monitored using a stopped-ﬂow device coupled to a ﬂuo-
rescence detection system. In a ﬁrst set of experiments the
folding and unfolding rate constants were measured at TFE
concentrations ranging from 0 to 9% (v/v). In all cases
folding was monitored after a 10-fold dilution of the protein
FIGURE 3 (a) Size distributions by light-scattering intensity of AcPDro2 in 0% (solid line) and immediately after addition of 5% (dashed line) TFE. The
inset shows the apparent diameters measured at different protein concentrations in 0% (d) and 5% (s) TFE. (b) Far-UV CD spectra of AcPDro2 in 0% TFE
(solid line), 5% TFE (dashed line), 80% TFE (d), and 5 M urea without TFE (¤). (c) Near-UV CD spectra of AcPDro2 in 0% TFE (solid line), 5% TFE
(dashed line) and 4.5 M urea without TFE (¤). In both the far- and near-UV analyses, the spectra were acquired a few seconds after dilution under the
conditions described to focus the analysis on the initial states present before aggregation. (d) Intrinsic ﬂuorescence spectra of AcPDro2 in 0% TFE (solid line),
5% TFE (dashed line), 80% TFE (d), and 5 M urea without TFE (¤). The spectra were acquired a few seconds after dilution under the conditions described to
focus the analysis on the initial states present before aggregation. The inset shows the intrinsic ﬂuorescence at 352 nm versus the percentage of TFE in the
solution. (e) Fluorescence spectra of 55 mMANS in the presence of 0.02 mg ml1 AcPDro2 in 0% TFE (solid line with solid circles) and 5% TFE (dashed line
with solid triangles). Spectra of free ANS in the absence of protein were also recorded as controls in 0% TFE (solid line) and 5% TFE (dashed line). Difference
spectra, obtained by subtracting the ANS spectra recorded in the absence of protein from the corresponding ones acquired in its presence, are also shown in 0%
TFE (s) and 5% TFE (n). ( f ) Enzymatic activity of AcPDro2, tested by adding the protein to a ﬁnal concentration of 0.5 mg ml1 to solutions containing
4 mM benzoylphosphate. ‘‘I.U./ l’’ indicates international units of activity per liter.
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denatured in 6 M urea to reach a ﬁnal urea concentration
of 0.6 M. Two exponential phases were observed. The ﬁrst
phase, corresponding to the major folding phase, shows
a marked positive dependence on TFE concentration and
reaches the maximum rate at ;6–8% TFE (Fig. 4 c, solid
circles). This behavior is typical of all proteins studied so far
and has been attributed to the fact that folding rate reaches
a maximum when the formation of secondary structure is
optimal and close to native-like levels (35). The unfolding
reaction was monitored by a 10-fold dilution of the native
protein in solutions containing 6 M urea to reach a ﬁnal urea
concentration of 5.4 M urea. Unfolding appears to be a
monophasic process in all recorded traces. The unfolding
rate constant appears to have a strong positive dependence
on TFE concentration, reaching no apparent maximum in the
range 0–9% TFE (Fig. 4 c, open circles).
In a second set of experiments the folding and unfolding
rate constants were determined in 0 and 5% (v/v) TFE in the
presence of various urea concentrations (see Materials and
Methods for experimental details). The resulting chevron
plots are shown in Fig. 4 d for the analyses carried out in both
the presence and absence of 5% TFE. In 5% TFE the chevron
plot is characterized by a noticeable downward curvature at
0–0.6 M urea, indicating that the major fast phase for folding
has a decreasing dependence on urea concentration as the
latter decreases. This phenomenon is often referred to as a
rollover and probably reﬂects the accumulation of a par-
tially folded or misfolded state during folding at these low
urea concentrations (36).
Both chevron plots, determined in 0 and 5% TFE, were
ﬁtted to Eq. 3 to calculate the values for the two rate constants
in the absence of urea (kH2OF and k
H2O
U , respectively). The data
points between 0 and 0.6 M urea in 5% TFE were obviously
excluded from the ﬁtting procedure. kH2OF was found to be 7.5
(6 0.3) s1 and 28.6 (6 2.4) s1 in 0 and 5% TFE,
respectively. kH2OU was found to be 4.2 (6 0.8) 3 10
3 s1
and 1.7 (6 0.5)102 s1 in 0 and 5% TFE, respectively. The
DGH2OUF values, obtainable from equilibrium experiments, can
also be obtained from kinetic data using
DG
H2O
UF ¼ RT lnðkH2OU =kH2OF Þ; (4)
where R and T are the universal gas constant and tem-
perature, respectively. DGH2OUF was found to be 18.5 (6 0.6)
kJ mol1 in the absence of TFE and 18.4 (6 1.1) kJ mol1
in 5% (v/v) TFE. These values appear to be within ex-
perimental error to those obtained from the equilibrium
chemically induced denaturation curves (compare with data
in Fig. 4 b). The observation that folding and unfolding are
both accelerated by ;4 times upon the addition of small
quantities of TFE provides an explanation as to why the
conformational stability of AcPDro2 (i.e., DGH2OUF) is not
changed from 0 to 5% TFE.
Aggregation mechanism of AcPDro2
The results shown in the previous paragraphs show that
AcPDro2 is able to form amyloid-like ﬁbrils and protoﬁla-
ments under conditions in which a native-like structure of the
protein is initially populated and does not appear thermody-
namically destabilized relative to the unfolded or partially
folded state. One issue that is important to address is whether
the ﬁbrils (Agg) form from the partially unfolded or totally
unfolded state (I) that is scarcely populated but in rapid
FIGURE 4 (a) Equilibrium urea unfolding
curves of AcPDro2 in 0% (d) and 5% (¤) TFE.
The lines represent the best ﬁts to the two-state
equation described by Santoro and Bolen (27),
for 0% TFE (solid line) and 5% TFE (dashed
line). (b) Variations in DGH2OUF (d) and Cm (s)
with TFE concentration. Error bars represent
standard deviations. (c) Rate constants for
folding in 0.6 M urea (d) and unfolding in
5.4 M urea (s) of AcPDro2 as a function of
TFE concentration. (d) Rate constants for
folding and unfolding of AcPDro2 as a function
of urea concentration, in 0% TFE (lower trace)
and 5% TFE (upper trace). Solid and open
symbols indicate folding and unfolding, re-
spectively. Solid diamonds and solid circles
indicate experiments performed by unfolding
the protein in 6 M urea at pH 5.5, whereas solid
squares and solid triangles refer to 2 M urea and
pH 2.0 as initial unfolding conditions.
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equilibrium with the native state (N) through the folding and
unfolding rate constants (Fig. 5, Scheme 1). Alternatively,
the protein may ﬁbrillate via a pathway in which various
molecules of native AcPDro2 assemble and subsequently
undergo a structural reorganization to form the observed
amyloid-like ﬁbrils (Fig. 5, Scheme 2). If Scheme 1 is correct
to describe the aggregation process of AcPDro2 under the
investigated conditions, the apparent rate constant for ag-
gregation (kobs) results from a combination of the unfold-
ing and folding rate constants (kH2OU and k
H2O
F ) and of the
rate constant for the conversion of the partially unfolded
ensemble into aggregates (kagg). Kinetic inspection of the sys-
tem and matrix algebra (37) leads to
kobs ¼ kaggkH2OU =ðkH2OU 1 kH2OF Þ: (5)
To determine kobs, AcPDro2 was incubated at a concen-
tration of 0.4 mg ml1 in 5% TFE. The steady-state
ﬂuorescence of ThT was measured at different time points
in the presence of aliquots of the protein sample that had
undergone aggregation in the absence of ThT. The plot of
ThT ﬂuorescence versus time was ﬁtted to Eq. 1 to determine
the kobs value (Fig. 6). The experiment and analysis were
repeated three times and the kinetic proﬁles were found to be
superimposable and reproducible. The ﬁtting procedure
yielded values of 2.9 6 (0.3)105, 2.4 6 (0.4)105, and
2.5 6 (0.2)105 s1 for the kobs value in the three cases.
Although the kH2OU and k
H2O
F values have been determined
under the conditions explored here (1.7 (6 0.5)102 and
28.6 (6 2.4) s1, respectively), the kagg value is difﬁcult to
determine experimentally under such conditions because the
nonaggregated protein initially populates a native-like rather
than unfolded or partially unfolded state. This problem was
circumvented, however, with two approaches. First the kagg
value has been calculated using the algorithm edited by
DuBay et al. (38), allowing the rate constant for aggregation
to be calculated for any unstructured amino acid sequence at
a desired protein concentration, pH, and ionic strength. The
value of kagg for AcPDro2 under the conditions investigated
here is predicted to be 4.5 (6 3.0) 3 105. Second, the kagg
value has been determined under conditions in which the
protein is substantially unfolded. A pH-titration experiment
showed that AcPDro2 is .95% unfolded in 5% TFE at pH
,4 (data not shown). The kinetic proﬁle of the aggregation
process has therefore been followed at pH 3.5 (see Materials
and Methods for details). Aggregation was found to be very
slow with no aggregates formed to any signiﬁcant extent for
up to 24 h (Fig. 6). An experimental bound can be kagg, 23
106. This bound has been determined in 5% (v/v) TFE at
pH 3.5 and is not, therefore, correct for the conditions of
interest here (5% TFE, pH 5.5). This bound can be corrected
using the previously determined relationship between kagg
and net charge (39), leading to an experimental bound of
,23 105 s1 for kagg in 5% TFE, pH 5.5, with an order of
magnitude similar to the predicted value.
Substitution of the experimentally determined values of
kH2OU and k
H2O
F , and of the predicted value of kagg in Eq. 5 leads
to a value of 2.65 (6 1.95)3 108 s1 for kobs, three orders of
magnitude lower than that determined experimentally (kobs ¼
2.6 (6 0.3)3 105 s1). Using the experimental bound,23
105 s1 for kagg, a bound of ,1 3 10
8 s1 is obtained for
kobs, again far from that determined from the kinetic proﬁle.
This discrepancy indicates that Scheme 1 in Fig. 5 is not cor-
rect and that AcPDro2 can aggregate without unfolding into
a fully or partially unfolded state under these conditions.
DISCUSSION
It is generally believed that globular proteins need to unfold,
at least partially, to aggregate into amyloid or amyloid-like
FIGURE 5 Two possible mechanisms of AcPDro2 aggregation. The
protein may form ﬁbrils from a totally or partially unfolded state (I) that is
scarcely populated but in rapid equilibrium with the native state (N) through
the folding and unfolding rate constants (Scheme 1). Alternatively various
molecules of native AcPDro2 may assemble and subsequently undergo a
structural reorganization to form the observed amyloid-like ﬁbrils (Scheme 2).
The analysis shows that Scheme 2 is more appropriate for AcPDro2 ag-
gregation.
FIGURE 6 Time course of aggregation of 0.4 mg ml1 AcPDro2 in 5%
TFE. The zero time point refers to the addition of TFE to the protein
solution. The experiment has been repeated three times, although only one
representative set of data is shown. The solid line through the data represents
the best ﬁt of the data shown in the ﬁgure to a single exponential function
(Eq. 1). The two dashed lines represent best ﬁts for the other two sets of data.
The ﬁgure also shows data for experiments in which AcPDro2 was in-
cubated under the same conditions in the absence of TFE (solid circles) and
in 5% TFE at pH 3.5 (crosses).
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ﬁbrils (3,16,17,40). Such a ‘‘conformational change hypoth-
esis’’ is widely supported by a large body of experimental
data. Proteins normally adopting a compact and well deﬁned
three-dimensional fold have a higher propensity to aggregate
under conditions that promote their partial unfolding, such
as high temperature, high pressure, low pH, or moderate
concentrations of organic solvents (41–44). In addition, for
some diseases in which the aggregating proteins normally
adopt folded conformations, evidence suggests that a de-
stabilization of the native structure, resulting in an increase
in the population of nonnative states, is one of the mecha-
nisms of action through which the pathogenicity of natural
mutations is mediated; this was shown for proteins such as
human lysozyme, transthyretin, superoxide dismutase, and
the immunoglobulin light chain (14,15,45,46). Amyloid for-
mation by proteins that have no link to human disease is
also promoted by destabilizing mutations both in vitro and
in vivo (44,47,48).
Although the ‘‘conformational change hypothesis’’ is
undoubtedly correct to describe the aggregation mechanism
of many globular proteins, the results presented here for
AcPDro2, and additional evidence reported recently for other
proteins, question the general applicability of this theory.
Under the conditions of pH, ionic strength, and temperature
investigated here, AcPDro2 is stable in its native conformation
in the absence of TFE, with a free energy change of unfolding
(DGH2OUF) of;18 kJ mol
1 and no apparent aggregates formed
after 24 h. In the presence of a small concentration of TFE,
such as 5% (v/v), the protein assembles into ﬁbrillar aggre-
gates able to bind ThT and CR and having extensive b-sheet
structure. Under these conditions, AcPDro2 maintains a
native-like conformation before aggregation. Indeed, the pro-
tein has a secondary structure content, packing around aro-
matic and hydrophobic residues, hydrodynamic diameter, and
catalytic activity indistinguishable from those of the native
protein kept under conditions that do not promote aggregation.
More importantly, the thermodynamic stability of the native
conformation was found to be similar under native and aggre-
gating conditions, with folding and unfolding both appearing
accelerated to similar extents.
In a previous study we have shown that the N-terminal
domain of the Escherichia coli protein HypF aggregates
under conditions in which the protein is still folded, a result
that is apparently similar to that described here for AcPDro2
(37). Yet, HypF-N was found to be energetically destabilized
under conditions promoting aggregation, and the kinetic
analysis revealed that aggregation can indeed occur from
a partially folded conformation, such as that accumulating
during folding, which is at equilibrium scarcely populated
but still in rapid equilibrium with the native structure (37).
By contrast, AcPDro2 appears to be as stable as under non-
aggregating conditions and the kinetic analysis shows that
the a mechanism of aggregation via partial unfolding is
largely inconsistent with the experimental data. An alterna-
tive model, in which the protein is not viewed to unfold
before self-assembly, needs to be invoked to outline the ag-
gregation mechanism of AcPDro2 in these conditions. One
possibility is that native-like molecules of AcPDro2 interact
through their edge b-strands.
The question naturally arises as to why AcPDro2 re-
quires small concentrations of TFE to aggregate. In its native
state, human muscle acylphosphatase, a protein sharing
36% sequence identity and belonging to the same structural
family as AcPDro2 (49), undergoes limited proteolysis by
trypsin, chymotrypsin, elastase, and subtilisin at the same
sites along the sequence in the presence and absence of 10%
TFE. However, the rate of proteolysis appears to be more
rapid at all sites in 10% TFE, indicating that the native
protein has gained ﬂexibility in the presence of TFE (49). It
is reasonable that in the presence of small concentrations of
TFE, the native fold of a protein such as AcPDro2 becomes
ﬂexible and plastic enough so that more opportunities exist
for intermolecular interactions to occur within the context of
native or native-like structures.
Although this hypothesis awaits further experimental
investigation, the most important message that emerges
from this study is that folded proteins can aggregate into
ﬁbrillar aggregates under conditions that do not promote
their unfolding or destabilization. In the highly crowded
environment of a cell, or in the extracellular space where
macromolecules still overcrowd the available space, albeit to
a lower extent, native proteins have to face a considerable
number of events that can possibly alter and distort their fold
or simply increase their ﬂexibility. Speciﬁc interactions with
ligands and partner proteins, nonspeciﬁc interactions with
a variety of alcohols or lipids that are present in vivo, and
translocation between organelles across phospholipid mem-
branes are just a few examples in which this can occur.
Perhaps the evolutionary adaptations that all-b proteins have
designed to prevent aggregation via interactions of the edge
strands of their native b-sheets is the most intriguing indication
that native or native-like aggregation is indeed possible and
needs to be actively combated by living organisms (50).
CONCLUSIONS
The ﬁnding that a protein with a well deﬁned three-
dimensional fold does not need to unfold to initiate
aggregation does not contradict the notion that many other
proteins need to unfold, at least partially, to form amyloid-
like structures. The fact remains that the fully or partially
unfolded states that are populated after biosynthesis on the
ribosome, stress conditions, or mutation are the conforma-
tional states that are most susceptible to initiate aggregation.
Nevertheless, folded proteins spend most of their lifetime in
a folded rather than an unfolded state. In some of these
diseases the residual propensity of folded states to aggregate,
albeit much lower than that of unfolded states, can become
signiﬁcant under physiological conditions, especially when
considering that amyloid formation is extremely slow even
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in the most aggressive manifestations of protein deposition
diseases.
The identiﬁcation of the aggregation pathway followed in
vivo by a protein that is normally folded is necessary to fully
understand the pathogenesis of the disease with which it is
associated and to identify possible molecular targets for drug
design. More generally, the elucidation of potential aggre-
gation pathways involving proteins that are not associated
with pathological states under conditions close to physio-
logical makes it possible to comprehend the strategies that
Nature has devised during evolution to contrast protein
aggregation.
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